SpectroFlow is developing a
patient friendly medical device
to preclinically detect & help
manage lymphedema
Lymphedema (LE) is a costly incurable disease that causes a build-up of lymph fluid in the body. LE affects 90 million people worldwide including an estimated 15% of all cancer survivors and up to 40% of those treated for breast cancer.
Lymphedema can be associated with extreme pain, infection and immobility in the affected body part. While a cure for lymphedema doesn't currently exist, early diagnosis and treatment is the most important factor in limiting progression and optimizing outcomes.
Of 150 LE patients surveyed thus far, 65% worried about their condition on a weekly, daily or constant basis.
Yet 75% of that same group of patients responded they were only able to see their clinician a few times per year (or less).
Conventional extravascular fluid measurement techniques are typically relegated to an "in clinic" setting. Spectroflow's technology is uniquely suited to a remote, patient-driven experience.
In 2020, SpectroFlow conducted a survey of 145 LE patients in the US and UK. 64% of the patients surveyed thought about LE once a week or more. Roughly half of that same group of patients reported seeing their clinician annually or less.
Early detection of LE/CVI, via remote patient monitoring, could potentially prevent the devastating effects of latter stage LE.
SpectroFlow has developed a unique non-invasive technology for measuring fluid variation with a mindset that patient compliance would be our highest priority in product development.
So far so good. Patients in the preclincal study responded well to a guided training from our beta virtual assistant, "Ada".
The same patient friendly thinking goes for the latest iteration of the device.
RoBrady, a world class design firm, created our easy on the eyes, real world (IP67), intuitive launch device, "Orb".
SpectroFlow’s platform is designed with the clinician AND patient in mind.
In 2020, via National Lymphedema Network, SpectroFlow conducted a survey of 50 healthcare professionals with a lymphedema diagnosis and/or management care focus.
The survey results were inspiring: 94% reported they relied primarily on a tape measure for LE assessment! However, less than 20% of the respondents felt the tape measurement technique was very accurate.
9 of 10 of the survey respondents would recommend a reliable patient friendly LE remote monitoring device such as SpectroFlow's Orb.
Copyright © 2022 SpectroFlow Corp - All Rights Reserved.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. SpectroFlow is not FDA cleared.
Please take our brief user experience survey for a chance to win a Samsung tablet!